Straits Times Index
3,111.65 +18.85 (+0.61%) Nikkei
26,491.97 +320.72 (+1.23%) Hang Seng
21,719.06 +445.19 (+2.09%) FTSE 100
7,208.81 +188.36 (+2.68%) BTC-USD
21,417.48 +508.77 (+2.43%) CMC Crypto 200
462.12 +8.22 (+1.81%)
Humanigen, Inc. (HGEN)
After hours:
| Previous close | 2.4400 |
| Open | 2.4900 |
| Bid | 2.2000 x 36200 |
| Ask | 2.2400 x 2900 |
| Day's range | 2.0801 - 2.5750 |
| 52-week range | 1.6700 - 18.6800 |
| Volume | |
| Avg. volume | 1,346,180 |
| Market cap | 153.981M |
| Beta (5Y monthly) | -1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.1140 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.43 |
- Business Wire
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
SHORT HILLS, N.J., June 16, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm,’ today announced it entered into an agreement with PCI Pharma Services (PCI), a leading integrated global contract development manufacturing organization (CDMO), to provide importation, release and commercialization services in the United Kingdom (UK) for lenzilumab. Under the agreement,
- Business Wire
Humanigen Announces Participation and Presentation at Multiple Conferences in June
SHORT HILLS, N.J., June 03, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced today that representatives will present and participate at multiple investors conferences in June 2022. Details of the conferences are as follows:
- Business Wire
Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
SHORT HILLS, N.J., May 24, 2022--Humanigen, Inc. (Nasdaq: HGEN) ("Humanigen"), a late-stage clinical biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ announced that Cameron Durrant, Chairman & CEO, will give a corporate presentation at 11:00am EDT today at the H.C. Wainwright Global Investment Conference taking place in Miami, FL, May 23-26, 2022. In his presentation Dr. Durrant will provide an update on progress towards release of top
